Overview

Theravance, Inc. (Theravance) is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. Theravance is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas, including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. The Company s key programs include: RELOVAIR, LAMA/LABA (719/vilanterol (VI)) and Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA), each partnered with GlaxoSmithKline plc (GSK), and its oral Peripheral Mu Opioid Receptor Antagonist program. Its drug discovery efforts are based on the principles of multivalency. Multivalency involves the simultaneous attachment of a single molecule to multiple binding sites on one or more biological targets.

Endorsements